辛伐他汀对急性冠脉综合征患者妊娠相关血浆蛋白-A水平与预后的影响  

The prognosis and pregnancy-associated plasma protein-A levels of Simvastatin in the treatment of acute coronary syndrome patients

作　　者：纪道兵 尚丽[2] 周心涛[1] 李东峰[1] 陈孝强[1] 田彩霞[3] 

机构地区：[1] 湖北医药学院附属东风医院心内科,湖北省十堰市442000 [2] 湖北医药学院附属人民医院妇产科 [3] 湖北医药学院附属人民医院检验科

出　　处：《中国心血管病研究》2016年第7期631-634,共4页Chinese Journal of Cardiovascular Research

基　　金：2013年湖北省教育厅课题（项目编号：B2013123）

摘　　要：目的 探讨辛伐他汀对急性冠脉综合征患者妊娠相关血浆蛋白-A（PAPP-A）水平与预后的影响.方法 选择2011年8月到2015年2月在我院进行诊治的110例急性冠脉综合征患者为本次试验的对象,通过随机数字表法的方式分配两组患者,分别为观察组55例及对照组55例.对照组运用常规治疗方式;观察组在常规治疗的基础上,给予辛伐他汀治疗（40 mg/d）,治疗观察周期为1个月.结果 观察组与对照组治疗后的血清PAPP-A含量分别为（7.24±2.32）mIU/L和（11.34±3.13）mIU/L,都明显低于治疗前的（20.66±5.33）mIU/L和（20.45±4.13）mIU/L（P＜0.05）,组间对比差异有统计学意义（P＜0.05）.两组治疗后的血清hs-CRP和Hcy含量都明显低于治疗前（P＜0.05）,同时治疗后观察组的血清hs-CRP与Hcy含量也都明显低于对照组（P＜0.05）.所有患者随访6个月,观察组的顽固心绞痛、非致命性心肌梗死、致命性心肌梗死和心源性猝死等明显少于对照组（P＜0.05）.结论 辛伐他汀辅助治疗急性冠脉综合征患者能有效减少血清PAPP-A的表达,从而抑制炎症反应;减低血清hs-CRP与Hcy含量,从而有效改善远期预后.Objective To investigate the prognosis and pregnancy-associated plasma protein-A （PAPP- A） levels of Simvastatin in the treatment of acute coronary syndrome patients. Methods From August 2011 to February 2015 in our hospital, 110 patients with acute coronary syndrome were selected as research subjects and were equally divided into observation group and control group of 55 patients according to a random number table. The control group were received routine treatment, and the observation group were added received Simvas- tatin treatment （40 rag/d） on the basis of the control group, the treatment observation periods were one month. Results The serum PAPP-A contents after treatment in the observation group and control group were （7.24±2.32）mlU/L and （11.34±3.13）mlU/L that were significantly lower than before treatment of （20.66±5.33）mlU/ L and （20.45 ±4.13）mlU/L（P〈0.05）, and compared between group differences were statistically significant（P〈 0.05）. The serum hs-CRP and Hey contents in the two groups after treatment in the two groups were significantly lower than before treatment （P〈0.05）, while the serum hs-CRP and Hcy contents observation group after treatment were also significantly lower than the control group （P〈0.05）. All patients were followed for 6 months, the stubborn angina, nonfatal myocardial infarction, nonfatal myocardial infarction and sudden cardiac death in the observation group were significantly more than the control group （P〈0.05）. Conclusion Simvastatin adjuvant treatment of a- cute coronary syndrome patients can effectively reduce serum PAPP-A expression, thereby inhibited inflammation, reduce serum hs-CRP and Hcy contents, thus effectively improve the long-term prognosis.

关 键 词：辛伐他汀 急性冠脉综合征 炎症因子 预后 

分 类 号：R543.3[医药卫生—心血管疾病]